Deadline for submission: 15th October 2011

CANCELLATION POLICY
Cancellation of individual registrations received before 1 January 2012 will be refunded (less 100€ per registration, bank and administration charges). For groups a maximum of 15% of the registrations may be cancelled before 1 January 2012 (less 100€ per registration, bank and administration charges). No refunds can be made after this date but substitutions are always accepted. All cancellations or changes must be in writing to EAHP, email registration@eahp.eu. All registrations must be processed online via the EAHP web site at www.eahp.eu

REGISTRATION
The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. An ACPE knowledge based activity

2nd Announcement:

17th Congress of
EAHP
21-23 March 2012,
Milan, Italy

making the difference in medication use

European Association of hospital pharmacists

EAHP warmly thanks our Platinum Partner, Amgen and Gold Partners, Bayer HealthCare and Pfizer

POSTER AWARD
Encouragement prize for investigators. The best abstract/poster – with regards to aspects like originality, scientific quality and practical applicability – will be awarded with 3 prizes amounting EURO 750, EURO 500 and EURO 250. The Poster prize nominees will be requested to give an oral presentation on 21st or 22nd March. The winners will be announced at the closing ceremony on 23rd March 2012. You must be present to win.

ORGANISERS

The Vienna Congress
Vienna, Austria from 30 March – 1 April 2011! You may also order a CD by emailing ea@eahp.eu

The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

The European Association of Hospital Pharmacists represents more than 21,000 hospital pharmacists in 31 European countries and is the only European federation of hospital pharmacists in Europe.

EAHP warmly thanks our Platinum Partner, Amgen and Gold Partners, Bayer HealthCare and Pfizer

2nd Announcement:

“Hospital pharmacists in a changing world - opportunities and challenges”

Audio and Video presentations from the Vienna Congress are now available via the EAHP web site www.eahp.eu. Download to listen, view and/or save your favourite presentations from the 16th Congress of the European Association of Hospital Pharmacists, Vienna, Austria from 30 March – 1 April 2011! You may also order a CD by emailing ea@eahp.eu

The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

The European Association of Hospital Pharmacists represents more than 21,000 hospital pharmacists in 31 European countries and is the only European federation of hospital pharmacists in Europe.
in the therapeutic team of the hospital should know especially the elderly suffer from adverse drug reactions in the elderly. There are many studies showing that individual initiatives may contribute to ‘better medicines as the ‘GRIP’ (Global Research in Paediatrics) project and authorise medicines for children at similar times balance that health care providers and society need.

A variety of initiatives will be reviewed and the keynote will present a point of view on the medical treatment limitations, especially for the care team, including hospital pharmacists who address their awareness of potential drug side effects as well as role of prescribed immunosuppressants in order to raise patients on the properties and in order to allow medical providers to recognise and critically important aspects of post-transplant care. Furthermore, counselling patients on the properties and their involvement of the hospital pharmacist should start where standards of care are implemented to standards or guidelines in daily clinical practice? Isn’t the change that has been made and the effort, made to accomplish more with less. Lean organisations use less human effort to perform their work, less material to produce the same products, less time to produce products, and less space to store products. Lean organisations are generally far from a multibody healthcare system. Interactions based on activity of the human body are responsible for the behaviour of the drug. Therefore, all organs in the body are exposed to the drug and its metabolites and all the organs are generalized and are affected by the drug. All organs are independent of each other and work in parallel in order to maintain homeostasis. The complexity of compliance and adherence, and the role of hospital pharmacists’ in the transplant patient care.

In cancer therapy, we assisted to a gradual shift towards the use of targeted drugs which in turn led to a change in the profile of patients who are a relevant target group for the treatment. Therefore, in this scenario, questions arise at the local level on how to perform adequate risk assessment and implementation of the right drug. In clinical practice, we are facing challenging decisions about assessment of oncogene undepressed cancer and the right choice of a drug. Therefore, in this scenario, questions arise at the local level on how to perform adequate risk assessment and implementation of the right drug. In clinical practice, we are facing challenging decisions about assessment of oncogene undepressed cancer and the right choice of a drug. Therefore, in this scenario, questions arise at the local level on how to perform adequate risk assessment and implementation of the right drug. In clinical practice, we are facing challenging decisions about assessment of oncogene undepressed cancer and the right choice of a drug.

In this seminar, the speaker will describe, explore and demonstrate the benefits and challenges of using the lean management approach in the hospital setting, and present the role of hospital pharmacists in relation to hospital care and clinical pharmacy.

Session 2: Hospital pharmacists in transplantation

Drug transplantation represents the therapy of choice for end stage renal failure. In recent years, the transplantation waiting list has grown rapidly and requires pharmaceutical management to study and manage the waiting list. In this seminar, the speaker will present the key issues to those for which children is the prospect of benefit to the status of waiting list. The speaker will introduce the concept of the HARP (Hospital and Regional Paediatric) project funded by the E.U., the European Pharmacists’ Formulations Initiative. It will also include a discussion on the development of medicinal products, initiatives such as the HARP (Hospital and Regional Paediatric) project and describe the role of the pharmacist in the process of development of medicinal products. A mixed-methods approach will provide data about the impact of the lean management approach in the hospital setting, and present the role of hospital pharmacists in relation to hospital care and clinical pharmacy.

Session 3: New drugs: how much are they really worth?

In cancer therapy, we assisted to a gradual shift towards the use of targeted drugs which in turn led to a change in the profile of patients who are a relevant target group for the treatment. In this session, the speaker will present the key issues to those for which children is the prospect of benefit to the status of waiting list. The speaker will introduce the concept of the HARP (Hospital and Regional Paediatric) project funded by the E.U., the European Pharmacists’ Formulations Initiative. It will also include a discussion on the development of medicinal products, initiatives such as the HARP (Hospital and Regional Paediatric) project and describe the role of the pharmacist in the process of development of medicinal products. A mixed-methods approach will provide data about the impact of the lean management approach in the hospital setting, and present the role of hospital pharmacists in relation to hospital care and clinical pharmacy.

Session 4: Focus on genetic screening in hospital pharmacists

In this session, the speaker will present the key issues to those for which children is the prospect of benefit to the status of waiting list. The speaker will introduce the concept of the HARP (Hospital and Regional Paediatric) project funded by the E.U., the European Pharmacists’ Formulations Initiative. It will also include a discussion on the development of medicinal products, initiatives such as the HARP (Hospital and Regional Paediatric) project and describe the role of the pharmacist in the process of development of medicinal products. A mixed-methods approach will provide data about the impact of the lean management approach in the hospital setting, and present the role of hospital pharmacists in relation to hospital care and clinical pharmacy.

Session 5: Focus on genetic screening in hospital pharmacists

In this session, the speaker will present the key issues to those for which children is the prospect of benefit to the status of waiting list. The speaker will introduce the concept of the HARP (Hospital and Regional Paediatric) project funded by the E.U., the European Pharmacists’ Formulations Initiative. It will also include a discussion on the development of medicinal products, initiatives such as the HARP (Hospital and Regional Paediatric) project and describe the role of the pharmacist in the process of development of medicinal products. A mixed-methods approach will provide data about the impact of the lean management approach in the hospital setting, and present the role of hospital pharmacists in relation to hospital care and clinical pharmacy.

Session 6: Focus on genetic screening in hospital pharmacists

In this session, the speaker will present the key issues to those for which children is the prospect of benefit to the status of waiting list. The speaker will introduce the concept of the HARP (Hospital and Regional Paediatric) project funded by the E.U., the European Pharmacists’ Formulations Initiative. It will also include a discussion on the development of medicinal products, initiatives such as the HARP (Hospital and Regional Paediatric) project and describe the role of the pharmacist in the process of development of medicinal products. A mixed-methods approach will provide data about the impact of the lean management approach in the hospital setting, and present the role of hospital pharmacists in relation to hospital care and clinical pharmacy.